BDBoudewijn L. M. DeJonge

Boudewijn L. M. DeJonge

*This is an algorithmically generated author record based on publicly available information.

Boudewijn L. M. DeJonge has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antimicrobial snapshot: Cefiderocol

    by Sean T. Nguyen, Samuel Simon, Boudewijn L.M. DeJonge

  • Open Access

    Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020–2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program

    by John H. Kimbrough, Maura H. Karr, Sean T. Nguyen, Boudewijn L. M. DeJonge, Chris Longshaw, Miki Takemura, Yoshinori Yamano, Mariana Castanheira, Rodrigo E. Mendes

    Cefiderocol and the β-lactam/β-lactamase inhibitor (BL-BLI) combinations ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (IMI-REL), and ceftolozane-tazobactam (TOL-TAZ) are recommended for the treatment of difficult-to-treat resistance (DTR) Pseudomonas aeruginosa by IDSA guidelines. The activity of cefiderocol and the three BL-BLI combinations described above was examined against DTR P. aeruginosa and molecularly characterized subsets collected from the USA and Europe (2020–2023). Approximately 4% of isolates showed a DTR phenotype, and cefiderocol remained active against 98.1% (CLSI breakpoint) of these isolates, whereas the three BL-BLI combinations had susceptibilities of 52.3%–56.0%. A total of 63% of DTR isolates were nonsusceptible to ≥1 of these BL-BLI combinations, and cefiderocol was active against ≥95.5% (CLSI) of these isolates, regardless of the nonsusceptible phenotype(s) to these combinations. In contrast, susceptibilities of the BL-BLI combinations varied from 0.0% to 30.3%. Almost 20% of DTR isolates carried carbapenemases, mostly metallo-β-lactamases, represented by 14 different STs from 15 countries. Cefiderocol had MIC 50/90 of 0.25/2 mg/L against these carbapenemase-carrying DTR isolates and 97.3% (CLSI) of the isolates were susceptible to cefiderocol, whereas 50/90 of cefiderocol against the non-carbapenemase DTR subset was 0.12/1 mg/L, and 98.3% (CLSI) of the isolates were susceptible to cefiderocol, vs 63.7%–69.6% for the BL-BLI combinations. Cefiderocol demonstrated high activity against a large and contemporary collection of DTR P. aeruginosa , regardless of carbapenemase status. The three currently recommended BL-BLI combinations for treating certain P. aeruginosa infections demonstrated limited activity and high degree of cross-resistance. IMPORTANCE: Cefiderocol and the β-lactam/β-lactamase inhibitor (BL-BLI) combinations ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (IMI-REL), and ceftolozane-tazobactam (TOL-TAZ) are recommended for the treatment of difficult-to-treat resistance (DTR) Pseudomonas aeruginosa by IDSA guidelines. However, this study shows that cefiderocol demonstrated high activity against a large collection of P. aeruginosa , including DTR isolates. In contrast, the three currently recommended BL-BLI combinations had limited activity, especially against isolates carrying carbapenemase genes, and high degree of cross-resistance. Cefiderocol also sustained activity against a diverse array of isolates with various BL-BLI nonsusceptible phenotypes, and regardless of carbapenemase status. These findings support the use of cefiderocol as a first treatment option for infections caused by DTR P. aeruginosa .


  • Open Access

    The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method

    by Boudewijn L.M. DeJonge, Christine Slover, Sean T. Nguyen, Christopher Longshaw, Miki Takemura, Naomi Anan, Hidenori Yamashiro, Yoshinori Yamano

    The reference method for determining cefiderocol MIC is broth microdilution (BMD) using iron-depleted cation-adjusted Mueller–Hinton broth (ID-CAMHB). However, laboratories have reported variable MIC findings and difficulties in determining MIC endpoints. To investigate this, the BMD method was re-evaluated by examining the chelation time for iron depletion of the media and by testing reproducibility using four MHB sources (BD-BBL, BD-Difco, Oxoid, and Merck) and 85 Gram-negative isolates ( Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , and Acinetobacter baumannii ), of which 63 were previously evaluated in vivo . Extending chelation time to 6 h provided optimal iron reduction to ≤0.03 µg/mL for all media. MIC reproducibility was high for each medium source and varied by species (93.3%–99.0% of MIC values within one dilution of modal MIC values); however, different sources of ID-CAMHB produced (reproducible) different modal MIC values for isolates. ID-CAMHB from BD-BBL and BD-Difco showed the best correlation with 96.5% of isolates showing modal MIC values within one dilution between media. MIC values generated with these two media were the most predictive of efficacy in vivo . When trailing was observed, it was seen across all media, and refined reading guidelines were applied to enhance reproducibility of determining the MIC endpoint. The 6-h chelation and the refined reading guidelines for trailing are now incorporated into the Clinical and Laboratory Standards Institute M100 document. When using the BMD method to determine cefiderocol susceptibility, the impact of media should be considered, and based on these results, ID-CAMHB prepared with BD-BBL or BD-Difco is recommended. IMPORTANCE: The reference antibiotic susceptibility testing method for cefiderocol is the broth microdilution method approved by the Clinical and Laboratory Standards Institute in 2016, using iron-depleted cation-adjusted Mueller–Hinton broth. A few manual devices have come to the market replicating this method, but inconsistent results with these devices have been reported. The current study identified the source of Mueller–Hinton broth as a variable in cefiderocol MIC determinations and provides detailed description of the preparation of iron-depleted cation-adjusted Mueller–Hinton broth, and revised reading guidance to improve reproducibility of cefiderocol MIC determinations for Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , and Acinetobacter baumannii . The recommendations made in this study should enhance the reproducibility of cefiderocol broth microdilution susceptibility testing.


  • Open Access

    Global Surveillance of the Activity of Sulbactam Combined With the Novel β-lactamase Inhibitor ETX2514 Against Clinical Isolates of Acinetobacter baumannii From 2014

    by Alita Miller, Meredith Hackel, Samuel Bouchillon, Boudewijn Dejonge, Ruben Tommasi, John Mueller

    Background. Multidrug-resistant Acinetobacter baumannii infections are considered a serious threat by the Centers for Disease Control and other government agencies. They are among the most difficult to treat and are associated with high mortality rates due to the limited number of effective therapies available and inappropriate initial treatment choice. The novel diazabicyclooctenone β-lactamase inhibitor effectively restores the antibacterial activity of sulbactam against multidrug-resistant (MDR) A. baumannii due to its potent inhibition of class A, C, and D serine β-lactamases, which are commonly found in this organism.


  • Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914

    by Robert A. Giacobbe, Michael D. Huband, Boudewijn L.M. Dejonge, Patricia A. Bradford